StockTake: Lumos enrols 500th patient in crucial respiratory diagnostic test study

Lumos Diagnostics has treated its 500th patient in a CLIA waiver study for FebriDx, a move making it more accessible by clinicians.

Stockhead’s Tylah Tully unpacks the latest from Lumos Diagnostics (ASX:LDX), who have enrolled its 500th patient in a CLIA waiver study for FebriDx, its rapid point-of-care diagnostic test to differentiate between bacterial and non-bacterial acute respiratory infections.

The company has a funding partnership with the US government’s Biomedical Advanced Research and Development Authority (BARDA).

Lumos has now received more than US$1.2 million in milestone payments from BARDA, which has pledged nearly US$3 million toward the study.

Watch the video to learn more.

This video was developed in collaboration with Lumos Diagnostics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as StockTake: Lumos enrols 500th patient in crucial respiratory diagnostic test study